Eidos Therapeutics, Inc. announced earnings results for the fourth quarter ended December 31, 2019. For the fourth quarter, the company announced operating loss was USD 19.324 million compared to USD 10.705 million a year ago. Net loss was USD 18.980 million compared to USD 9.854 million a year ago. Basic loss per share was USD 0.51 compared to USD 0.27 a year ago. For the full year, operating loss was USD 40.451 million compared to USD 37.779 million a year ago. Net loss was USD 37.835 million compared to USD 39.812 million a year ago. Basic loss per share was USD 1.03 compared to USD 1.86 a year ago.